- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03550339
Regulation of Energy Balance and Metabolism - Mechanisms Behind and Beyond Obesity and Weight Loss (BALANCE)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Obesity is widely acknowledged health problem affecting millions of people globally. Enormous efforts have been made to solve the problem, but long-term results of the conventional weight loss and/or weight management strategies have been poor indicating still inadequate understanding of the problem. Surgical, rather than weight-centred lifestyle interventions, have proved to be the most effective tool available to treat obesity within individuals suitable for obesity surgery. Current surgical interventions are, however, suitable only for a small subset of obese individuals. In general, there is a need for development of new approaches and therapies that are safer and more individualized to each patient in the struggle against obesity and related disorders. To achieve these goals, research must focus to investigate and understand the complex homeostatic and hedonic regulation of eating behavior and energy balance in different physiological and pathological conditions.
This study aims to investigate homeostatic and hedonic mechanisms regulating energy balance and metabolism in obesity and the effects of three distinct obesity treatments on these regulatory mechanisms. The regulatory mechanisms are investigated at the level of metabolism, autonomic and central nervous systems as well as subjective, both implicit and explicit, experiences.
A total of 90 obese female volunteers (18-65 years, body mass index > 35 kg/m2), of which 30 females waiting for bariatric surgery (SURG), 30 females attending a dietary treatment program for obesity (DIET) and 30 females attending Health at Every Size (HAES) program, will participate in the study. The obesity treatment for SURG and DIET groups follows the principles of the Current Care Guidelines for Obesity (adults) and the treatment for the HAES group applies the strategies of the non-diet wellness-based HAES program. The treatment programs of the DIET and HAES groups include 8-10 weekly group sessions organized by authorised nutritionist.
The study includes also two four-hour visits at the research laboratory of the Institute of Public Health and Clinical Nutrition, University of Eastern Finland, the first visit organized before the participants attend any of the obesity treatments and the second visit 12 months later. During the laboratory visits psychophysiological signals (EEG, ANS, facial EMG and eye tracking) are monitored and blood samples taken throughout the experimental period. Participants will also perform two computer-based test sessions, the first one at baseline and the second before a snack meal. Two meals (breakfast and snack meal) are offered to the participants during the experiment in order to study the regulatory mechanisms of interest both at the homeostatic and hedonic states.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- body mass index >34 kg/m2
- native finnish speaker
- right-handed
Exclusion Criteria:
- pregnancy or breast feeding
- severe visual impairments, severe scalp skin lesions or intracranial bleeding during previous six months
- severe neurological, psychiatric or cardiovascular disease
- type 1 or 2 diabetes mellitus
- use of weight loss medications or other treatments known to affect weight
- heavy alcohol use
- any other condition (medical or other) the principal investigator considers as an obstacle to participation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: SURG
subjects attending bariatric surgery
|
bariatric surgery according to Finnish Current Care Guidelines for Obesity in adults
|
|
Active Comparator: DIET
subjects attending dietary weight loss program
|
dietary weight loss program according to Finnish Current Care Guidelines for Obesity in adults
|
|
Active Comparator: HAES
subjects attending Health At Every Size weight management program
|
treatment is based on the previously published procedure (e.g.
Bacon et al. 2002) and Health At Every Size trademark, consisting of body acceptance, eating behaviour, physical activity, nutrition, and social support
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Implicit associations
Time Frame: Change from baseline D-score at 1 year
|
D-score of Implicit Association Test
|
Change from baseline D-score at 1 year
|
|
Explicit ratings
Time Frame: Change from baseline visual analogue scale at 1 year
|
Ratings on visual analogue scales for wanting and liking of presented foods
|
Change from baseline visual analogue scale at 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Event-related potentials
Time Frame: Change from baseline event-related potentials at 1 year
|
Event-related potentials measured by EEG
|
Change from baseline event-related potentials at 1 year
|
|
Glucose
Time Frame: Change from baseline glucose at 1 year
|
Plasma glucose, fasting, postprandial
|
Change from baseline glucose at 1 year
|
|
Insulin
Time Frame: Change from baseline insulin at 1 year
|
plasma insulin, fasting, postprandial
|
Change from baseline insulin at 1 year
|
|
Ghrelin
Time Frame: Change from baseline ghrelin at 1 year
|
plasma ghrelin, fasting, postprandial
|
Change from baseline ghrelin at 1 year
|
|
Leptin
Time Frame: Change from baseline leptin at 1 year
|
serum leptin, fasting
|
Change from baseline leptin at 1 year
|
|
Peptide YY
Time Frame: Change from baseline PYY at 1 year
|
plasma peptide YY, fasting, postprandial
|
Change from baseline PYY at 1 year
|
|
Endocannabinoids
Time Frame: Change from baseline endocannabinoids at 1 year
|
plasma endocannabinoids, fasting, postprandial
|
Change from baseline endocannabinoids at 1 year
|
|
Weight
Time Frame: Change from baseline weight at 1 year
|
body weight, fasting
|
Change from baseline weight at 1 year
|
|
Eating behaviour
Time Frame: Change from baseline eating behaviour at 1 year
|
self-reported questionnaires
|
Change from baseline eating behaviour at 1 year
|
|
Psychosocial characteristics
Time Frame: Change from baseline psychosocial characteristics at 1 year
|
self-reported questionnaires
|
Change from baseline psychosocial characteristics at 1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Leila J Karhunen, PhD, University of Eastern Finland
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 327/2016
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.